Skip to main content

Advertisement

SpringerLink
Log in

Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Advances in cancer treatment have resulted in improved life expectancies for survivors of breast and prostate cancer. As the number of cancer survivors grows, the long-term side effects of treatment play an increasingly prominent role in the routine care of these patients. Due to similar management approaches, survivors of breast and prostate cancer are at increased risk for osteoporosis. This review summarizes the prevention and management of osteoporosis and osteopenia resulting from cancer treatment in survivors of breast and prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Herr HW, Kornblith AB, Ofman U: A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 1993, 71(Suppl):1143–1150.

    Article  PubMed  CAS  Google Scholar 

  2. National Institutes of Health: Osteoporosis prevention, diagnosis, and therapy: NIH consensus statement. Bethesda, MD: March 27–29, 2000:1–45.

  3. Pfeilschifter J, Diel IJ: Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000, 18:1570–1593.

    PubMed  CAS  Google Scholar 

  4. Consensus development conference: prophylaxis and treatment of osteoporosis. Osteoporos Int 1991, 1:114–117.

  5. Kanis JA: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994, 4:368–381.

    Article  PubMed  CAS  Google Scholar 

  6. Seeman E: Pathogenesis of bone fragility in women and men. Lancet 2002, 359:1841–1850.

    Article  PubMed  Google Scholar 

  7. Ahles TA, Saykin A: Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 2001, 19:812–820.

    Article  PubMed  CAS  Google Scholar 

  8. Brown JP, Josse RG, and the Scientific Advisory Council of the Osteoporosis Society of Canada: 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002, 167(Suppl):S1-S34.

    PubMed  Google Scholar 

  9. Compston JE: Sex steroids and bone. Physiol Rev 2001, 81:419–447.

    PubMed  CAS  Google Scholar 

  10. Center JR, Nguyen TV, Sambrook PN, Eisman JA: Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab 2000, 84:3626–3635.

    Article  Google Scholar 

  11. Favus MJ, ed: Primer on Metebolic Bone Diseases and Disorders of Mineral Metabolism, edn 5. Philadelphia: Lippincott; 2003.

    Google Scholar 

  12. Favus MJ, ed: Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 4. Philadelphia: Lippincott; 1999.

    Google Scholar 

  13. The Writing Group for the PEPI trial: Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996, 276:1389–1396.

    Article  Google Scholar 

  14. Prince RL: Counterpoint: estrogen effects on calcitropic hormones and calcium homeostasis. Endocr Rev 1994, 15:301–309.

    Article  PubMed  CAS  Google Scholar 

  15. Melton LJ III, Atkinson EJ, O’Connor MK, et al.: Bone density and fracture risk in men. J Bone Miner Res 1998, 13:1915–1923.

    Article  PubMed  Google Scholar 

  16. Center JR, Nguyen TV, Schneider D, et al.: Mortality after all types of osteoporotic fracture in men and women: an observational study. Lancet 1999, 353:878–882.

    Article  PubMed  CAS  Google Scholar 

  17. Diamond TH, Thornley SW, Sekel R, Smerdely P: Hip fracture in elderly men: prognostic factors and outcomes. Med J Aust 1997, 167:412–415.

    PubMed  CAS  Google Scholar 

  18. Cranney A, Wells G, Willan A, et al.: Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002, 23:508–516.

    Article  PubMed  CAS  Google Scholar 

  19. Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344–1352.

    Article  PubMed  CAS  Google Scholar 

  20. Cummings SR, Black DM, Thompson DE, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077–2082.

    Article  PubMed  CAS  Google Scholar 

  21. Tonino RP, Meunier PJ, Emkey R, et al.: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000, 85:3109–3115.

    Article  PubMed  CAS  Google Scholar 

  22. Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83–91.

    Article  PubMed  CAS  Google Scholar 

  23. Chesnut CH III, Silverman S, Andriano K, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000, 109:267–276.

    Article  PubMed  CAS  Google Scholar 

  24. Downs RW Jr, Bell NH, Ettinger MP, et al.: Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000, 85:1783–1788.

    Article  PubMed  CAS  Google Scholar 

  25. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441.

    Article  PubMed  CAS  Google Scholar 

  26. Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637–645.

    Article  PubMed  CAS  Google Scholar 

  27. Rossouw JE, Anderson GL, Prentice RL, et al., for the Women’s Health Initiative: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002, 288:321–333.

    Article  PubMed  CAS  Google Scholar 

  28. Orwoll E, Ettinger M, Weiss S, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604–610.

    Article  PubMed  CAS  Google Scholar 

  29. Kurland ES, Cosman F, McMahon DJ, et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069–3076. First study to investigate vertebral fracture risk in women with nonmetastatic breast cancer. The incidence of vertebral fracture was nearly five times greater than normal in women from the time of first diagnosis.

    Article  PubMed  CAS  Google Scholar 

  30. Orwoll E, Calancy AD, Adami S, et al.: Recombinant human parathyroid hormone (1-34) therapy reduces the incidence of moderate/severe vertebral fractures in men with low bone density. J Bone Miner Res 2001, 16(Suppl):S162.

    Article  Google Scholar 

  31. Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207–1215.

    Article  PubMed  CAS  Google Scholar 

  32. Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216–1226.

    Article  PubMed  CAS  Google Scholar 

  33. Kanis JA, McCloskey EV, Powles T, et al.: A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79:1179–1181.

    Article  PubMed  CAS  Google Scholar 

  34. Bruning PF, Pit MJ, de Jong-Bakker M, et al.: Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 1990, 61:308–10.

    PubMed  CAS  Google Scholar 

  35. Chen Z: Increased fracture risk among breast cancer survivors: results from the Women’s Health Initiative [abstract]. J Bone Miner Res 2003, 18(Suppl 2):S22 (abstract 1077).

    Google Scholar 

  36. Saarto T, Blomqvist C, Valimaki M, et al.: Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 1997, 75:602–605.

    PubMed  CAS  Google Scholar 

  37. Powles TJ, Hickish T, Kanis JA, et al.: Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996, 14:78–84.

    PubMed  CAS  Google Scholar 

  38. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001, 19:3306–3311.

    PubMed  CAS  Google Scholar 

  39. Powles TJ, McCloskey E, Paterson AH, et al.: Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998, 90:704–708.

    Article  PubMed  CAS  Google Scholar 

  40. Harper-Wynne CL, Sacks NP, Shenton K, et al.: Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002, 20:1026–1035.

    Article  PubMed  CAS  Google Scholar 

  41. Baum M, Budzar AU, Cuzick J, et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131–2139.

    Article  PubMed  CAS  Google Scholar 

  42. Grant M: Zoledronic acid preserves bone in premenopausal women treated with combined hormonal therapy [abstract 12]. Presented at the San Antonio Breast Conference. San Antonio, TX, December 11–14, 2002.

  43. Data on file. Peapack NJ: Pharmacia Corporation; 2003.

  44. Chapuy MC, Pamphile R, Paris E, et al.: Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002, 13:257–264.

    Article  PubMed  CAS  Google Scholar 

  45. Kanis JA, Powles T, Paterson AH, et al.: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996, 19:663–667.

    Article  PubMed  CAS  Google Scholar 

  46. Delmas PD, Balena R, Confravreux E, et al.: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997, 15:955–962.

    PubMed  CAS  Google Scholar 

  47. CGP 42446 Protocol 007 (data on file). East Hanover, NJ: Novartis Pharmaceuticals; 1998.

  48. Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653–661.

    Article  PubMed  CAS  Google Scholar 

  49. O’Regan RM, Gajdos C, Dardes R, et al.: Effect of raloxifene after tamoxifen on breast and endometrial cancer growth [abstract]. Proc ASCO 2001, 19:95.

    Google Scholar 

  50. Nelson DA, Jacobsen G, Barondess DA, Parfitt AM, Ethnic differences in regional bone density, hip axis length, and lifestyle variables among healthy black and white men. J Bone Miner Res 1995, 10:782–787.

    Article  PubMed  CAS  Google Scholar 

  51. Hillner BE, Ingle JN, Chelbowski RT, et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042–4057.

    Article  PubMed  CAS  Google Scholar 

  52. Reid IR: Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 2003, 15:458–463.

    Article  PubMed  CAS  Google Scholar 

  53. Tarassoff P, Csermak K: Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003, 61:1238–1239.

    Article  PubMed  Google Scholar 

  54. Bolla M, Gonzalez D, Warde P, et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295–300.

    Article  PubMed  CAS  Google Scholar 

  55. Pilepich MV, Caplan R, Byhardt RW, et al.: Phase III trial of androgen suppression using goserelin in unfavorableprognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997, 15:1013–1021.

    PubMed  CAS  Google Scholar 

  56. Maillefert JF, Sibilia J, Michel F, et al.: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999, 161:1219–1222.

    Article  PubMed  CAS  Google Scholar 

  57. Daniell HW, Dunn SR, Ferguson DW, et al.: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000, 163:181–186.

    Article  PubMed  CAS  Google Scholar 

  58. Diamond T, Campbell J, Bryant C, Lynch W: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998, 83:1561–1566.

    Article  PubMed  CAS  Google Scholar 

  59. Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 1997, 157:439–444.

    Article  PubMed  CAS  Google Scholar 

  60. Hatano T, Oishi Y, Furuta A, et al.: Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000, 86:449–452.

    Article  PubMed  CAS  Google Scholar 

  61. Oefelein MG, Ricchuiti V, Conrad W, et al.: Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001, 166:1724–1728.

    Article  PubMed  CAS  Google Scholar 

  62. Taxel P, Fall PM, Albertsen PC, et al.: The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:4907–4913.

    Article  PubMed  CAS  Google Scholar 

  63. Smith M: Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 2002, 60(Suppl 3A):79–86.

    Article  PubMed  Google Scholar 

  64. Smith MR, McGovern FJ, Zietman AL, et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948–955. First study to show that pamidronate prevents bone loss in the hip and lumbar spine in men receiving treatment for prostate cancer with a gonadotropin-releasing hormone agonist.

    Article  PubMed  CAS  Google Scholar 

  65. Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008–2012.

    Article  PubMed  CAS  Google Scholar 

  66. Eriksson S, Eriksson A, Stege R, et al.: Bone mineral density in patients with prostate cancer treated with orchiectomy and with estrogens. Calcif Tissue Int 1995, 57:97–99.

    Article  PubMed  CAS  Google Scholar 

  67. Smith MR, Fallon MA, Goode MJ: Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003, 61:127–131.

    Article  PubMed  Google Scholar 

  68. Smith MR, McGovern FJ, Fallon MA, et al.: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001, 91:2238–2245.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington, Room 1068, 10032, New York, NY, USA

    Dawn Hershman MD, MS

Authors
  1. Dawn Hershman MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rashmi Narayanan MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hershman, D., Narayanan, R. Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Curr Oncol Rep 6, 277–284 (2004). https://doi.org/10.1007/s11912-004-0036-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-004-0036-z

Keywords

Search

Navigation